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Glucocorticoid receptors are ligand-dependent tran- 
scription factors that are subject to down-regulation 
by their cognate ligand; however, the mechanisms 
mediating this physiological response are not com- 
pletely understood. Since analysis of the human glu- 
cocorticoid receptor (hGR) cDNA sequence revealed 
the presence of sequences with homology to both posi- 
tive and negative glucocorticoid regulatory elements, 
we have examined the potential of hGR to bind to the 
hGR cDNA by Southwestern blot analysis. The data 
revealed that glucocorticoid receptors exhibited spe- 
cific binding to their own cDNA. To determine whether 
this binding was of functional significance in the down- 
regulation of glucocorticoid receptors, we analyzed the 
effect of glucocorticoids on hGR protein levels from 
COS 1 cells transfected with an hGR cDNA expression 
vector. These transfected cells produced intact hGR 
that were capable of ligand-dependent regulation of a 
co-transfected glucocorticoid-responsive reporter 
gene. Glucocorticoid treatment of hGR-transfected 
cells resulted in down-regulation of hGR (assayed by 
both glucocorticoid binding capacity and hGR protein 
levels) within 24 h of steroid administration. To deter- 
mine if the glucocorticoid-induced down-regulation of 
transfected hGR was compatible with effects at the 
levels of receptor gene expression and RNA stability, 
we examined hGR mRNA steady state levels. Reduc- 
tions from 2- to 6-fold were observed in hGR mRNA 
levels following glucocorticoid treatment of trans- 
fected COS 1 cells. This down-regulation of transfected 
hGR mRNA could not be attributed to either the Rous 
sarcoma virus promoter, which drives hGR expression, 
or to other sequences present in the vector plasmid 
since transcription of a related plasmid containing a 
chloramphenicol acetyltransferase gene in place of the 
hGR cDNA was not regulated by glucocorticoids. 
Down-regulation of hGR mRNA by glucocorticoids in 
transfected cells occurred in a time- and dose-depend- 
ent manner that is consistent with a glucocorticoid 
receptor-mediated process. Glucocorticoid-induced 
down-regulation of hGR mRNA steady state levels was 
not observed in COS 1 cells transfected with cDNAs 
encoding mutant hGR (defective in either steroid or 
DNA binding), which indicates that functional steroid 
and DNA binding domains of the expressed hGR were 
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required for down-regulation. Interestingly, treatment 
of transfected COS 1 cells with the glucocorticoid an- 
tagonist RU486 also resulted in down-regulation of 
transfected hGR mRNA. Deletion analysis revealed 
that the region of the hGR cDNA that was responsible 
in part for the observed down-regulation in response 
to glucocorticoid was contained within a 1-kilobase 
restriction fragment (from base pair +527 to +1526). 
Together these studies provide evidence that the hGR 
cDNA contains regulatory signals sufficient for down- 
regulation of glucocorticoid receptors. 
Both positive and negative modulation of gene transcription 
in response to glucocorticoids has been well established (for 
review see Refs. l-3). The action of glucocorticoid hormones 
is mediated through specific high affinity binding to glucocor- 
ticoid receptors (GR).’ These proteins, together with the other 
steroid receptors, belong to a family of ligand-dependent 
transcription factors (4). Following steroid binding, the recep- 
tor hormone complex interacts with DNA and ultimately 
results in alteration of the transcription of certain genes. 
Although the mechanism of steroid hormone action has not 
been completely elucidated, it is known that the GR complex 
interacts with specific target DNAs called glucocorticoid reg- 
ulatory elements (GREs) that are associated with genes whose 
transcription is elevated in response to hormone. Much less 
is known about how GR negatively regulates gene expression; 
however, sequences that may serve as negative GREs 
(nGREs) have been recently identified for a few genes whose 
transcription is inhibited by glucocorticoids (5). 
The biologic effects of glucocorticoids are dependent on the 
presence of functional receptors (6). One determinant of 
cellular responsiveness to steroid treatment is the concentra- 
tion of GR (7, 8). Thus, to understand the mechanism of 
steroid hormone action it is of particular importance to un- 
derstand how cellular GR levels are regulated. Glucocorticoids 
and other steroid hormones down-regulate the levels of their 
cognate receptors in a number of target tissues and in many 
different cell lines (9-11). Receptor down-regulation has been 
documented previously for certain peptide hormone receptors 
and receptors for neurotransmitters, and this phenomenon 
1 The trivial names and abbreviations used are: GR, glucocorticoid 
receptor; h, human; GRE, glucocorticoid regulatory element; n, neg- 
ative: RSV. Rous sarcoma virus: SV40, simian virus 40; LTR, long 
terminal repeat; DMEM, Dulbecco’s modified Eagle’s medium; CAT< 
chloramphenicol acetyltransferase; NaDodSOI, sodium dodecyl sul- 
fate; PAGE, polyacrylamide gel electrophoresis; dexamethasone, 
9cu-fluoro-ll~,17,21-trihydroxy-l6~-methyl-pregna-1,4-diene-3,20- 
dione; dexamethasone mesylate, 9-fluoro-11@,17,21-trihydroxy-16a- 
methylpregna-1,4-diene-3,20-dione 21-methanesulfonate; RU38486, 
RU486, 17~-hydroxy-ll~-(4-dimethylamino-phenyl)l7~-(l-pro- 
pionyl) estra-4,9-dien-3-one; kb, kilobase( bp, base pair(s). 
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has been correlated with “desensitization” to prolonged hor- 
mone treatment (reviewed in Ref. 12). Autoregulation of GR 
was initially defined as a decrease in steroid binding capacity 
following glucocorticoid treatment; more recently, reduced 
steady state levels of GR mRNA (13, 14) and GR protein (15, 
16) have been demonstrated. Although the mechanism for GR 
down-regulation occurs, at least in part, at the level of gene 
transcription (17), several groups have also examined the 
influence of ligand on GR turnover. McIntyre and Samuels 
(18) used dense amino acid labeling to show that GR half-life 
(as measured by steroid binding) in a pituitary tumor cell line 
is shortened following glucocorticoid treatment. Glucocorti- 
coid-induced changes in protein turnover have also been 
documented using protein synthesis inhibitors in a rat liver 
cell line (15). In contrast, when a pulse-chase labeling proce- 
dure and quantitation by antibody binding were employed to 
study GR protein half-life in hormone-treated S49 mouse 
lymphoma cells, no changes in receptor half-life were seen 
(19). Such discrepancies may reflect cellular variations in 
receptor recycling mechanisms (20) or post-translational 
modifications of receptor that are essential for ligand binding 
but not perhaps for recognition of receptor by antibodies. 
Whether GR mediates down-regulation through binding to 
GRE-like elements that are associated with the GR gene, as 
shown previously for positively regulated genes, is not known. 
Okret et al. (13) reported that certain sequences in the 3’- 
nontranslated region of a rat GR cDNA fragment are pro- 
tected from DNase I digestion by partially purified GR, how- 
ever, it is unclear whether these binding sites are functionally 
involved in down-regulation of GR mRNA and protein. 
The results presented here indicate that the hGR cDNA 
encodes sufficient information to display glucocorticoid-in- 
duced down-regulation of hGR mRNA and protein levels 
when it is transfected into COS 1 cells. Both the glucocorticoid 
agonist, dexamethasone, and antagonist, RU486, elicited the 
down-regulatory response in transfected cells. We did not 
observe down-regulation in the absence of functional DNA or 
steroid-binding domains of the receptor suggesting that down- 
regulation is receptor-mediated. Deletion of 1 kb of hGR 
cDNA-coding sequences resulted in a truncated hGR mRNA 
that was impaired in its ability to undergo down-regulation 
perhaps due to the removal of signals important in hGR 
regulation. Taken together the data presented here suggest 
that the human glucocorticoid receptor contains intragenic 
regulatory sequences. 
MATERIALS AND METHODS 
[“HlDexamethasone mesylate (37.5 Ci/mmol), [‘“Clchloramphen- 
icol, and EN3HANCE were purchased from Du PontlNew England 
Nuclear. [o(-32P]UTP (600 Ci/mmol), [a-s’P]dCTP (3000 Ci/mmol), 
and ““I-staphylococcal protein A (2-10 &i/fig) were purchased from 
ICN Radiochemicals (Irvine, CA). Dexamethasone and estradiol were 
obtained from Steraloids (Wilton, NH). RU38486 was kindly provided 
by Dr. R. Deraedt, Roussel UCLAF (Romainville, France). Restric- 
tion enzymes and DNA-modifying enzymes were purchased from 
Bethesda Research Laboratories, New England Biolabs (Beverlv. 
MA), and Promega Corp. (Madison, WI). Nitrocellulose Bk85 was 
from Schleicher & Schuell. Prestained molecular weight standard 
proteins were from Bethesda Research Laboratories. 
Cell Culture and Transfecfion-COS 1 cells (African green monkey 
kidney cells) (21) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 9 mg/ml glucose, 100 IU/ml penicillin, 100 pg/ 
ml streptomycin and supplemented with 2 mM L-glutamine and 10% 
(v/v) of a mixture (1:l) of fetal calf serum/calf serum. Cultures were 
maintained at 37 “C in a humidified atmosphere of 5% CO,. Cell 
number was determined using a Zf Coulter Counter (Coulter- Elec- 
tronics, Hialeah, FL). Cells were transfected bv the DEAE-dextran 
method of Sompayrac and Danna (22) as modified by Gorman (23). 
Cells were refed with supplemented DMEM after a 3-h incubation 
with DNA. 
Recombinant Plasmids-The hGR expression vector, pRShGR 
(24), consists of an -3.0-kb hGR cDNA driven by the Rous sarcoma 
virus long terminal repeat promoter (RSV-LTR) and contains the 
simian virus 40 (SV40) origin of replication and polyadenylation sites. 
Plasmids 1422 and 1582 (24) are in-frame BamHI linker insertion 
mutants of pRShGR that are incapable of DNA and steroid binding. 
respectively. The number designation of each mutant refers to the 
hGR amino acid position after which the linker was inserted (24). All 
hGR plasmids were generously provided by Drs. Stanley Hollenberg 
and Ron Evans (Salk Institute, San Diego, CA). Plasmid RSVCAT/ 
ori, which contains the SV40 origin of replication, was constructed 
by ligating the -350-bp pRShGR NdeI fragment to pRSVCAT 
(kindly provided by Dr. Frank Rutter, University of California, San 
Francisco, CA) that had been linearized with NdeI and phosphatased. 
The identity of the clone was verified by restriction enzymemapping 
and hybridization. The resulting recombinant plasmid pRSVCAT/ 
ori is therefore identical to pRShGR except that the hGR cDNA has 
been replaced by the chloramphenicol acetyltransferase (CAT) gene. 
The hGR deletion mutant. AAcc-Cla hGR. was created bv removina 
the lOOO-bp AccI to ClaI fragment (+527’to +1526) from the hGR 
cDNA and religating the plasmid. AAcc-Cla hGR encodes an -2.3- 
kb transcript that is not in-frame. 
RNA Isolation and Northern Blot Analysis-RNA was isolated 
from transfected cells by the rapid cell lysate method of Badley et al. 
(25) or by lysis in guanidinium isothiocyanate and centrifugation 
through a cesium chloride cushion (26). When indicated, poly(A+)- 
enriched RNA was obtained bv binding and elutina RNA from 
oligo(dT)-cellulose (Collaborative Research, Lexington, MA). RNA 
was denatured using glyoxal and dimethyl sulfoxide, separated by 
electrophoresis through 1% agarose gels, and transferred to nitrocel- 
lulose filters as described by Maniatis et al. (27). Filters were hybrid- 
ized by standard methods using randomly primed ‘*P-labeled hGR 
cDNA and chick p-actin cDNA (-1 x lo6 cpm/ml hybridization fluid) 
or with “‘P-labeled cRNA probes (-3-5 X lo6 cpm/ml). The dual 
promoter vector pT7/T3-18 (Bethesda Research Laboratories) con- 
taining either the hGR cDNA or p-actin cDNA was used to generate 
cRNA probes according to the procedure recommended by the sup- 
plier. Relative quantitation of bands on autoradiographs was per- 
formed using a GS300 transmittance scanning densitometer (Hoefer 
Scientific Instruments, San Francisco, CA). 
Chloramphenicol Acetyltransferase (CAT) Assays-Cell extracts 
were generated and CAT assays were performed essentially as de- 
scribed by Gorman et al. (28). The concentration of acetyl coenzyme 
A was increased to 1 mM, and the reaction times and concentration 
of [i4C]chloramphenicol were determined in preliminary studies to 
ensure that the percent conversion of [i4C]chloramphenicol to acet- 
ylated forms per microgram protein was in the linear range of sensi- 
tivity. After autoradiography, radioactive spots on thin layer chro- 
matography plates were cut out and counted to determine absolute 
levels of conversion. Protein concentrations were determined by the 
method of Lowry et al. (29). 
Preparation of Labeled Glucocorticoid Receptor Extract and South- 
western Blotting-These procedures were done as previously de- 
scribed (30). Briefly. anproximatelv 3 x 10’ cells from a HeLa S, 
suspension culture were-incubated”with 20 nM covalent affinity li- 
gand, [3H]dexamethasone mesylate (31), for 2 h at 0 “C. Cells were 
homogenized and the supernatant (cytosol) was collected following 
centrifugation at 100,000 X g for 1 h at 0 “C. Denatured cytosols were 
electrophoresed on 3-mm-thick preparative gels consisting of a 3% 
acrylamide stacking gel and a 7.5% resolving gel. The gels were then 
incubated in renaturation buffer (50 mM NaCl, 10 mM Tris-HCl, pH 
7.0, 20 mM EDTA, 0.1 mM dithiothreitol, 4 M urea), and proteins 
were electrophoretically transferred to nitrocellulose filters. Strips 
were cut from the filters and either processed for fluorography or 
preincubated in binding buffer (5% nonfat drv milk. 50 mM NaCl. 10 
mM Tris-HCl, pH 7.4,-l mM EDTA, O.Ol%“antifoam A) overnight 
followed by incubation at room temperature with 32P-labeled DNA 
fragments. Filter strips were washed in binding buffer and exposed 
to x-ray film. Labeling of hGR from transfected cells (dexamethasone- 
treated and untreated) was performed as described above except T150 
flasks containing cell monolayers were first incubated at 37 “C in 
unsupplemented DMEM for 1.5 h with two changes of media. This 
exhaustive wash procedure was employed to displace unlabeled dex- 
amethasone and allow replenishment of cvtonlasmic recentor. thus 
promoting efficient radiolabeling of GR (9,‘32). 
-  
Isolation and Labeling of DNA Frazments-Restriction digests of 
plasmid DNAs were eikctrophoresed-on 4% acrylamide g&, and 
bands containing the desired DNA fragments were excised and eluted 
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ah described in Maniatis it al (25). The DNA fragments used for 
Southwestern blots were: (1) the 2.6.kb KpnI-DraI fragment from 
pRShGR encompassing the entire hGR coding region; (ii) the 2.2-kb 
KpI-&nI f’ragment from pRShGR that contains no hGR cDNA 
sequences; (iii) the 844.bp AccI-ClaI fragment of pRShGR that con- 
sists of a portion of the hGR coding sequence; and (iv) the 792-bp 
AccI-Fs~1 fragment from oBR322 that lacks a GRE consensus se- 
quence ‘(X3). Approxlmateiy 200 ng of each fragment (0.1-0.4 pmol) 
was labeled with [(i-“P]dCTP using T4 DNA polymerase by replace- 
ment synthesis (34). 
Western Rlotting-Nitrocellulose filters containing immobilized 
cytosolic proteins were incubated at room temperature for 4 h in 
blocking buffer (10% nonfat drv milk, 10 mM Tris-HCI, DH 7.4. 150 
mM NapI, 0.05% Tween 20). Filters were then incubate> overnight 
at 4 “C with rabbit antiserum raised against a peptide corresponding 
to a region within the immunogenic domain of the hGR,’ and then 
filters were washed in blocking buffer. “‘I-Staphylococcal protein A 
(40 PCi) in blocking buffer was added to filters and incubated for 30 
min; filters were washed and exposed to x-ray film. 
RESULTS 
Glucocorticoid Receptors Bind to the Human Glucocorticoid 
Receptor cDNA-Computer analysis of the hGR cDNA has 
revealed the presence of multiple sequences with homology to 
the GRE octamer that was originally identified by Payvar et 
al. (35)” and to a putative negative GRE associated with the 
pro-opiomelanocortin gene (36). Based on these observations, 
we wanted to determine whether these GRE-like elements, 
which reside within the glucocorticoid receptor gene, allow 
specific binding of receptor to its own cDNA. Such a result 
might suggest that these elements function in the regulation 
of GR gene expression by its cognate ligand. The ability of 
GR from HeLa cell cytosolic fractions to bind various frag- 
ments of DNA was analyzed by Southwestern blotting. This 
technique has been shown to permit analysis of specific GR 
protein-DNA interactions using cytosolic proteins immobi- 
lized on nitrocellulose (30). Only a minimal level of nonspe- 
cific protein-DNA interactions are seen with this procedure 
due to the inclusion of nonfat dry milk as a blocking agent 
during hybridization. The identity of GR on Southwestern 
blots can be verified by the capacity of the receptor to satur- 
ably bind to the affinity ligand dexamethasone mesylate. The 
pRShGR KpnI-DraI fragment that contains the entire hGR 
cDNA coding sequence but lacks most of the -2.3-kb untrans- 
lated region at the 3’ end (Fig. lA, hGR) was bound in 
preference to two other DNA fragments, which consist either 
of vector sequences from pRShGR (Fig. lA, RSV) or a 
pBR322 fragment (Fig. lA, PBR) that is devoid of GREs (33). 
Some binding of GR to the vector sequences in pRShGR 
occurs and is most likely due to a sequence that matches the 
GRE consensus located in the pBR322 portion of the expres- 
sion vector (bp 4044-4051 of pBR322) (33). Fig. 1B is an 
autoradiograph of an adjacent lane from the same gel that 
shows [“Hldexamethasone mesylate-bound GR comigrating 
with the [“‘P]DNA binding activity seen in panel A (at ap- 
proximately 94-97 kDa). GR was saturably bound to [“HI 
dexamethasone mesylate as indicated by the absence of radi- 
olabeled protein in the presence of excess unlabeled dexa- 
methasone (data not shown). 
Dexamethasone Treatment Results in Decreased Levels of 
hGR Protein in Transfected Cells-To establish whether GR 
binding to its cDNA affected regulation of GR gene expres- 
sion, we analyzed the potential for transfected hGR protein 
levels to be down-regulated in response to hormone. Based on 
the observation that glucocorticoids down-regulate hGR pro- 
tein and mRNA levels in a variety of cell lines and in rats 
‘J. A. Cidlowski, manuscript in preparation. 
’ D. B. Tully, unpublished data. 
A B 
PB- w 
hGR RSV PBR 
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FIG. 1. Analysis of DNA and steroid binding by glucocorti- 
coid receptor. HeLa Sn cells were incubated with [“Hldexametha- 
sone mesylate, and cytosol extracts were prepared and subjected to 
NaDodSO,-PAGE as described. Equivalent amounts of protein were 
loaded (290 pg/lane) in replicate lanes. Gels were soaked in renatur- 
ation buffer and electrophoretically transferred to nitrocellulose. A, 
nitrocellulose strips containing cytosolic proteins were hybridized 
with ““P-labeled DNA fragments: hGR, K&I-DraI from pRShGR, 
which contains the hGR cDNA: RSV. Ks~soI-K~n1 from DRShGR, 
which contains vector sequences’ including’the kSV promoter; and 
pBR, AccI-FspI from pBR322, which lacks GRE-like sequences. B, 
the filter from an adjacent lane was sprayed with EN:‘HANCE and 
exposed to x-ray film to visualize binding of the affinity label [“HI 
dexamethasone mesylate. Prestained molecular weight standards 
were: PB, phosphorylase b (109,000 Da); BSA, bovine serum albumin 
(72,000 Da). 
(13, 14, 17), we wanted to determine if hGR that had been 
introduced into cells by transfection was also susceptible to 
down-regulation. We first determined that hGR from trans- 
fected cells resembled native GR both structurally and func- 
tionally. The cytosolic fraction isolated from COS cells trans- 
fected with the hGR cDNA expression vector, pRShGR, was 
incubated with [“Hldexamethasone and subjected to sucrose 
density gradient centrifugation. This physical analysis con- 
firmed that intact steroid binding hGR (9-10 S) was synthe- 
sized in these transfected cells (Ref. 37 and data not shown). 
To analyze for the function of hGR from transfected cells, a 
plasmid containing the glucocorticoid-sensitive mouse mam- 
mary tumor virus-LTR promoter linked to CAT was co- 
transfected with pRShGR into COS cells. As expected based 
on the work of others (24), glucocorticoid-inducible CAT 
activity was seen in these cells indicating that the transfected 
hGR was able to activate transcription from a glucocorticoid- 
sensitive promoter (data not shown). We then analyzed the 
effect of dexamethasone on hGR levels in COS cells trans- 
fected with pRShGR by two criteria: 1) immunoreactivity 
with anti-hGR antibodies and 2) binding to the radiolabeled 
affinity ligand [“Hldexamethasone mesylate. To demonstrate 
that GR protein levels were reduced in dexamethasone- 
treated transfected cells, cytosolic protein extracts from 
washed cells were analyzed by Western blotting. For this 
analysis we used antiserum generated against a peptide that 
is located in the immunogenic domain (NH2 terminus) of the 
hGR.* Immune complexes were visualized following incuba- 
tion of the immobilized proteins with ‘251-staphylococcal pro- 
tein A. The level of transfected immunoreactive hGR from 
cells grown in the absence of dexamethasone (Con) was 
greater than that from cells grown in the presence of dexa- 
methasone (Dex) (Fig. 2A). To confirm that GR levels were 
reduced in dexamethasone-treated transfected cells, GR bind- 
ing to [“Hldexamethasone mesylate was examined. Trans- 
fected cells were washed extensively to remove unlabeled 
dexamethasone (see “Materials and Methods”) prior to incu- 
bation with [“Hldexamethasone mesylate. This wash proce- 
dure has been shown to remove greater than 99% of the 
unlabeled steroid and allows efficient labeling of GR from 
cytosols (9, 32). [“HlDexamethasone mesylate-GR complexes 
(94-97 kDa) were visualized by fluorography of electropho- 
retically transferred proteins following NaDodSOJPAGE. 
GR was identified by the specific and saturable binding to 
[3H]dexamethasone mesylate (labeling that was competed out 
in the presence of excess unlabeled dexamethasone) (Fig. 2B, 
compare lanes H ([“Hldexamethasone mesylate) and H+C 
Glucocorticoid Receptor Autoregulation 
A. B, 
Dex Con Dex Con -II 
-MYO- 
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transcript is smaller than the reported size of native GR 
transcripts due to removal from the hGR cDNA of most of 
the 3’-untranslated region, which contains the GR binding 
sites studied by Okret et al. (13). Fifteen independent exper- 
iments showed a mean decrease of 4-fold +- 0.5 SE. in hGR 
mRNA levels following 12-17-h treatment with 2 x 10e7 M 
dexamethasone. The two blots in Fig. 3 are representative of 
the range of down-regulation that we observe. The blots were 
also hybridized with ,‘“P-labeled @-actin cDNA to confirm that 
equivalent amounts of RNA were present in control and 
dexamethasone-treated sample lanes. The differential signal 
intensities obtained in control and dexamethasone-treated 
samples were unaffected by the type of hybridization probe 




H H+C h H+C 
FIG. 2. Electrophoretic analysis of human glucocorticoid 
receptor protein in transfected cells. COS 1 cells were transfected 
with the hGR cDNA containing expression vector, pRShGR. Trans- 
fected cells were grown in the presence (Dex) and absence (Con) of 
dexamethasone. Cells were washed extensively and cytosolic extracts 
prepared. Proteins were subjected to NaDodSO,-PAGE and electro- 
phoretically transferred to nitrocellulose. All samples were loaded 
with equivalent amounts of protein (165 pg/lane, panel A and 300 pg/ 
lane, panel B). A, Western blot analysis of GR. Filters were incubated 
with anti-human glucocorticoid receptor antiserum followed by in- 
cubation with “‘I-staphylococcal protein A and processed as described 
under “Materials and Methods” B, affinity labeling of human gluco- 
corticoid receptor with [ ‘Hldexamethasone mesylate. Transfected 
cells were washed extensively and incubated with [ ‘Hldexamethasone 
mesylate alone (If) or together with 1000.fold molar excess radioinert 
dexamethasone (H+C) and processed as described above. Filters were 
sprayed with EN”HANCE and exposed to x-ray film. The locations 
of the prestained molecular weight markers (MYO, myosin (224,000 
Da); PR, phosphorylase b (109,000 Da); and BSA, bovine serum 
albumin, (72,000 Da) is shown. 
hGR- IL 
P-actin - 
EXP. 1 EXP.2 
FIG. 3. Dexamethasone-mediated down-regulation of 
steady state human glucocorticoid receptor mRNA levels in 
transfected cells. COS 1 cells were transfected with pRShGR or 
mock-transfected and incubated with dexamethasone (Dex) or no 
additions (CON). Poly(A’) RNA was isolated, denatured, and sepa- 
rated on 1% agarose gels (2 pg/lane). RNA was then transferred to 
nitrocellulose and hybridized with “‘P-labeled hGR and chick @actin 
cDNA probes. The positions of the transfected hGR transcript (-3.3 
kb) and p-actin (-2.8 kb) are indicated. The two experiments were 
performed identically and show the range of down-regulation ob- 
served. 
([“Hldexamethasone mesylate + unlabeled dexamethasone)). 
The amount of [“Hldexamethasone mesylate binding to trans- 
fected GR was greater from cells grown in the absence of 
dexamethasone (Con, lane H) compared with cells grown in 
the presence of dexamethasone (Dex, lane H) (Fig. 2B). The 
[“Hldexamethasone mesylate-labeled hGR comigrated with 
the immunoreactive hGR (Fig. 2). Both methods showed 
negligible levels of endogenous COS GR protein in mock 
transfected cells (data not shown). 
Examination of hGR mRNA Levels from Transfected Cells- 
To determine whether down-regulation of hGR protein was 
reflected at the level of mRNA we analyzed steady state hGR 
mRNA levels in response to hormone treatment. The hGR 
cDNA was transfected into COS cells, and total cellular RNA 
or poly(A+) RNA was isolated from control and dexametha- 
sone-treated cells (36-40 h post-transfection). As shown in 
Fig. 3, Northern blot analysis revealed that hGR mRNA levels 
from transfected cells were markedly decreased in response 
to dexamethasone treatment. Only the transfected hGR 
mRNA (-3.3 kb) encoded by pRShGR was present in these 
Northern blots, which is consistent with the observation that 
endogenous GR is not detectable in COS cells (24, 37). This 
Negatively Acting Sequences Are Located within the hGR 
cDNA-Expression of the hGR cDNA in pRShGR is driven 
by the RSV-LTR promoter contained on a 524-bp restriction 
fragment (24). Other investigators have shown that the RSV- 
LTR promoter is not regulated by dexamethasone (38, 39). 
To verify that the RSV promoter is not sensitive to dexa- 
methasone and to rule out the possibility that other vector 
sequences in pRShGR influenced regulation by glucocorti- 
coids, we examined CAT activity in cells cotransfected with 
the plasmids pRSVCAT/ori and pRShGR. Plasmid 
RSVCAT/ori is identical to pRShGR except the hGR cDNA 
has been replaced by the cDNA encoding CAT. If sequences 
that are located outside the hGR cDNA were responsible for 
down-regulation of hGR mRNA levels, then CAT activity 
would be expected to decrease in response to dexamethasone 
treatment in cells that were transfected with pRSVCAT/ori. 
It was necessary to cotransfect cells with hGR since, as 
mentioned above, COS cells contain negligible levels of en- 
dogenous GR. As given in Table I, no difference in CAT 
activity in cell extracts prepared from control or dexametha- 
sone-treated transfected cells was detected. This result dem- 
onstrates that the effects of dexamethasone on hGR mRNA 
levels observed in pRShGR-transfected cells were specific for 
the hGR cDNA and were not due to the RSV promoter or to 
sequences present in the vector plasmid. As expected, trans- 
fection of pRSVCAT/ori alone (no cotransfected hGR) simi- 
larly resulted in no difference in CAT activity in response to 
dexamethasone (data not shown). 
Down-regulation of Transfected hGR mRNA Is Time- and 
Dose-dependent-To determine if the glucocorticoid-induced 
decrease in hGR mRNA levels in transfected cells was a 
glucocorticoid receptor-mediated event we examined hGR 
mRNA levels following treatment with varying dexametha- 
sone concentrations. The kinetics of this response were also 
examined. Treatment of hGR-transfected COS cells for 15 h 
with dexamethasone concentrations ranging from 1 X lo-‘” 
to 1 x 10m6 M resulted in a dose-dependent down-regulation 
of hGR mRNA (Fig. 4). Data from two independent experi- 
TABLE I 
CAT activity from cells co-transfected with human glucocorticoid 




1 1.50 1.42 
2 a.21 8.24 
’ Cells were cotransfected with pRShGR and pRSVCAT/ori and 
treated as described under “Materials and Methods.” 
’ Data are expressed as percentage of acetylation of [‘4C]chloram- 
phenicol/25 fig of protein extract/h. The difference in CAT activity 
between experiments 1 and 2 is most likely due to variability in 
transfection efficiency. Dex, dexamethasone. 
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hGR-- 
FIN:. 1. Hormone concentration dependence of human glu- 
cocorticoid receptor mRNA down-regulation in transfected 
cells. COS 1 cells transfected with pRShGR were grown in the 
absence (Con) or presence of 1 x lo-“’ to 1 X lo-” M dexamethasone 
(I1e.1) for 17 h. Total cellular RNA was isolated, denatured, and 
separated on a 15 agarose gel (20 pg/lane). RNA was transferred to 
nitrocellulose and hybridized with “P-labeled hGR cRNA. Arrous 
indicate hvbridization to transfected hGR and to the 28 S ribosomal 
RNA (-4.-7 kb). 
Dex treatment (hours) 
FIN;. 5. Time course of human glucocorticoid receptor 
down-regulation by dexamethasone in transfected cells. COS 
1 cells transfected with pRShGR were grown either in the presence 
(11) or absence (C) of dexamethasone (Dex) (2 x lo-'M) for 10 min 
and 1. ‘2. 4, 6. 8. and 24 h. Total cellular RNA was isolated and 
examined on a Northern blot (inset) as described above. Hybridiza- 
tion of hGR mRNA in the presence and absence of dexamethasone 
was quantitated by densitometric scanning. The amount of hGR 
mRNA in the absence of dexamethasone was taken to be 100% of 
control. 
ments revealed that maximum reductions of hGR mRNA 
occurred between 10eR and lo-‘M dexamethasone; hence, this 
concentration range was routinely used in all experiments. 
An approximate 30% reduction was seen at 10-l’ M, and the 
half-maximal decrease in hGR mRNA levels occurred at 
approximately 0.5 X lo-’ M dex. This value is in agreement 
with the steroid dissociation constant of native hGR for 
dexamethasone (& = l-5 X 10m9 M) (9), which suggests that 
down-regulation is mediated by GR. 
The time course of hGR mRNA down-regulation was ex- 
amined at a dexamethasone concentration of 2 X lo-’ M to 
determine the earliest time of mRNA response. Northern blot 
analysis of total RNA from COS cells transfected with an 
hGR cDNA showed a decrease in hGR mRNA steady state 
levels within 1 h of dexamethasone addition (Fig. 5). Mini- 
mum levels of hGR mRNA were established between 4 and 6 
h and remained decreased for at least 24 h. Due to the 
transient nature of hGR expression in transfected cells, hGR 
mRNA was not measured at times greater than 24 h after 
dexamethasone treatment (corresponding to 36-40 h post- 
transfection). The kinetics of down-regulation resemble that 
seen for other receptor-mediated events such as induction of 
mouse mammary tumor virus RNA by glucocorticoids (40). 
Together these data are consistent with the hypothesis that 
the glucocorticoid effects on hGR mRNA levels observed in 
transfected cells were mediated by GR. 
Functional hGR Is Required for Down-regulation of hGR 
mRNA-GR, like other members of the steroid receptor su- 
perfamily, contain discrete domains that are responsible for 
DNA binding, ligand binding, and transactivation functions 
(4). Data presented above suggest that down-regulation is 
receptor-mediated; to directly test this hypothesis we analyzed 
the ability of two GR mutants to down-regulate levels of hGR 
mRNA in response to dexamethasone. Transfections were 
performed using two hGR cDNAs mutants: one that encodes 
a non-DNA binding hGR and one that specifies a non-steroid 
binding variant. Both mutants were generated by insertion of 
linkers, which did not disrupt the protein reading frame (24). 
Fig. 6 shows that mRNA levels from either of these mutant 
receptors were not reduced in response to dexamethasone 
treatment. This result contrasts sharply with the results ob- 
tained for the wild type receptor and suggests that DNA- and 
steroid-binding functions of the GR receptors are required for 
down-regulation to occur and provides direct evidence that 
down-regulation is GR-mediated. 
Down-regulation of hGR mRNA by the Glucocorticoid An- 
tagonist RU486-RU486 binds with high affinity to glucocor- 
ticoid receptors; however, these RU486-GR complexes do not 
mediate transcriptional activation (41, 42). Based on these 
properties, we wished to determine whether down-regulation 
of hGR mRNA could proceed in transfected cells following 
RU486 treatment. This approach should help to reveal 
whether the transcriptionally active form of the receptor was 
required for down-regulation. Fig. 7 shows that hGR mRNA 
levels were reduced in response to RU486 (2 X lo-’ M). 
Concentrations between low9 and lo-’ M RU486 were suffi- 
cient to evoke a small (-25-30%) decrease in the levels of 
hGR mRNA as compared with untreated controls (data not 
shown). Treatment of transfected cells with steroids that 
interact with GR such as cortisol and progesterone caused 
down-regulation of hGR mRNA in contrast to estradiol (2 x 
lo-’ M), which had no effect on transfected hGR mRNA levels 
(data not shown). 
Down-regulation of an hGR Deletion Mutant Is Impaired- 
To begin to localize sequences within the hGR cDNA that are 
responsible for down-regulation of transfected hGR mRNA, 
we evaluated the regulation of a deleted hGR cDNA. When 
an hGR cDNA that lacks sequences from bp +527 to +1526 
(an AccI-ClaI fragment) was cotransfected with the intact 
hGR cDNA, levels of the truncated hGR transcript were 
partially decreased compared with the intact receptor mRNA 
(Fig. 8). We chose this region of the hGR for deletion because 
it contains a sequence with homology to the consensus GRE 
DCDC DC 
FIG. 6. Regulation of transfected DNA- and steroid-binding 
human glucocorticoid receptor mutants by dexamethasone. 
COS 1 cells were transfected with hGR cDNAs that encode either a 
DNA binding mutant (DNA), a steroid-binding mutant (Steroid), or 
wild type receptor and grown in the presence (II) or absence (C) of 
dexamethasone. RNA was analyzed on Northern blots as described 
above. 
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Fw. 7. Regulation of transfected human glucocorticoid 
receptor mRNA levels by RU486. COS 1 cells were transfected 
with pRShGR and grown in the presence of dexamethasone (Dex, 2 
X lo-‘M), RU486 (Ru, 2 X lo-“M), or were untreated (C). RNA was 
analyzed on Northern blots as described earlier, and signals on 
autoradiographs were quantitated by scanning densitometry. The 
average values and standard deviations of three experiments relative 
to untreated controls are shown. 
DEX CON 




FIG. 8. Regulation of cotransfected, truncated, and wild 
type human glucocorticoid receptor mRNA levels by dexa- 
methasone. Total RNA was prepared from cells cotransfected with 
pRShGR and 1Acc-Cla hGR (hGR lacking bp +527 to +1526). Cells _ . 
were incubated with dexamethasone (DEX) or no additions (CON). 
The Northern blot was hvbridized with “P-labeled hGR cRNA. The 
transcripts from pRShGR and IAcc-Cla hGR are -3300 and -2300 
nucleotides, respectively. Hybridization to “‘P-labeled jj-actin is 
shown at the bottom of the figure. 
that was derived from GREs from a number of glucocorticoid- 
regulated genes (4). Results of three independent experiments 
revealed that the levels of the truncated Act-Cla hGR mRNA 
were reduced to 48 + 5% whereas intact hGR mRNA levels 
were decreased to 26 * 3% of control levels. This result 
suggests that the region between nucleotides +527 and +1526 
of the hGR cDNA contains at least some of the signals that 
are necessary for down-regulation. Southwestern blotting re- 
vealed that hGR from HeLa cytosols bound to the 844-bp 
hGR AccI-ClaI restriction fragment (contained within the 
1000-bp AccI-ClaI fragment) in preference to an equivalently 
sized non-GRE-containing fragment of pBR322 (Fig. 9A). 
Panel 9B confirms that [“Hldexamethasone mesylate-labeled 
GR comigrated with the [“‘P]DNA binding activity seen in 
Fig. 9A. The higher molecular weight [“P]DNA binding ac- 
A. 0. 




FIG. 9. Analysis of selective DNA binding of isolated “‘P- 
labeled DNA fragments by human glucocorticoid receptor. 
Cytosol prepared from [“Hldexamethasone mesylate-labeled HeLa S3 
cells was processed as described. Equivalent amounts of protein were 
loaded on replicate lanes (600 &lane). A, adjacent lanes from the 
resulting filter transfer were incubated with either the 844-1~~ Accl- 
ClaI fragment of pRShGR (3 X lo” cpm) or the 792-hp AK-Kspl 
fragment of pRR322 (3 x lo” cpm). H, the filter from an adjacent 
lane was processed for fluorography as described. The molecular 
weight standards MYO, PR, and HSA are described in the legend to 
Fig. 2. 
tivity seen in Fig. 9A most likely represents a nonspecific 
protein-DNA interaction since binding to both fragments 
(Act-Cla and pBR) was comparable. The protein responsible 
for this DNA binding activity appears to be unrelated to GR 
as this protein did not bind to [“Hldexamethasone mesylate 
(Fig. 9B) or to anti-GR antibodies (data not shown). Thus 
the observation that hGR specifically interacts with the Acc- 
Cla fragment of the hGR cDNA supports the theory that the 
region from +527 to +1526 may contain autoregulatory sig- 
nals. 
DISCUSSION 
We have examined steady state hGR mRNA and protein 
levels from COS 1 cells following transfection with an hGR 
expression vector. Down-regulation of hGR mRNA and pro- 
tein levels was observed in transfected cells in response to 
glucocorticoid treatment. Non-hGR sequences located in the 
vector were not responsible for the glucocorticoid-mediated 
alteration in receptor levels; thus, it appears that the hGR 
cDNA contains sequences sufficient to evoke the glucocorti- 
coid-induced down-regulation of hGR mRNA and protein 
seen in transfected cells. This effect required the DNA- and 
steroid-binding functions of the receptor as demonstrated by 
the failure of mRNA from either a DNA- or a steroid-binding 
deficient mutant to be down-regulated. Moreover, the time 
and dose dependence of down-regulation by dexamethasone 
in transfected cells provides further evidence that this effect 
is receptor-mediated. 
There was some variability observed in the extent of down- 
regulation of hGR mRNA in response to dexamethasone 
between the different experiments. We attribute this varia- 
bility to differences in transfection efficiencies and, perhaps 
to a lesser extent, to endogenous steroid in the cell culture 
media and to slight differences in the times of exposure to 
dexamethasone. Nevertheless, down-regulation was consist- 
ently observed regardless of variations in the initial levels of 
hGR mRNA. 
We do not know if down-regulation of mRNA levels in 
transfected COS 1 cells is due to transcriptional or post- 
transcriptional effects. It has been reported that the rate of 
endogenous GR transcription is decreased in dexamethasone- 
treated human IM9 lymphocytes (17) and in rat liver (15). In 
addition, Rosewicz et al. (17) and Dong et al. (15) failed to see 
any dexamethasone effects on GR mRNA half-life in cultured 
cells. The kinetics of down-regulation that we observed for 
the transfected hGR mRNA resembled that observed for the 
endogenous GR mRNA (17). Also, transfected hGR mRNA 
displayed a sensitivity to varying dexamethasone concentra- 
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tions that was similar to endogenous GR mRNA (17). 
We have shown that treatment with RU486 (a glucocorti- 
coid antagonist) resulted in down-regulation of hGR mRNA 
in transfected cells; however, a 5-fold higher dose of RU486 
was used. Down-regulation of endogenous GR mRNA by 
RU486 was demonstrated in NIH3T3 cells (16) and in the rat 
brain (43) but was not seen in the human lymphoblastoid IM- 
9 cell line when a lo-fold lower concentration of RU486 was 
used (44). Since it has been shown that RU486-GR complexes 
bind DNA with a specificity that is similar to dexamethasone- 
GR complexes (44), it is not unreasonable that this antagonist 
elicited down-regulation. These effects of RU486 suggest that 
the transcriptional activating function of the receptor may 
not play a major role in down-regulation although a partial 
agonist function of RU486 cannot be excluded. That down- 
regulation was seen following treatment with RU486 argues 
that this phenomenon is not due to glucocorticoid activation 
of a transcriptional repressor in transfected cells. 
By analogy with positively regulated genes, inhibition of 
gene expression by glucocorticoids may involve binding of 
receptor to cis-acting sequences. GREs have been reported in 
various locations within or associated with genes that are 
positively regulated by glucocorticoids. The locations of these 
GREs vary from a few kilobases upstream from the promoter 
(e.g. tyrosine aminotransferase gene (45)) to within the first 
intron of the growth hormone gene (46). In contrast, regula- 
tory regions for genes whose transcription is negatively regu- 
lated by glucocorticoids (e.g. glycoprotein LY subunit (47), 
collagen (48), stromelysin (49), pro-opiomelanocortin (50), 
and prolactin (39, 51)) have only been reported to date in 
regions that are 5’ to the promoters of the various genes. A 
weak consensus sequence has been identified in some genes 
whose transcription is inhibited by glucocorticoids. This pu- 
tative negative GRE (nGRE) does not resemble the consensus 
GRE associated with genes that are positively regulated by 
glucocorticoids (5). It should be noted that this partial nGRE 
consensus is not contained within the hGR cDNA; however, 
some sequences with homology to a potential nGRE in the 
pro-opiomelanocortin promoter region (36) are located within 
the Act-Cla fragment of the hGR. Perhaps autoregulatory 
signals are present within the 1-kb Act-Cla fragment of the 
hGR cDNA since deletion of this region yielded a truncated 
hGR mRNA that was somewhat refractory to down-regula- 
tion. In addition, GR from HeLa cytosol bound to this frag- 
ment in preference to a pBR322 restriction fragment, further 
supporting a possible regulatory interaction between GR and 
its gene or perhaps with its mRNA. These putative intragenic 
regulatory sequences in the hGR could potentially function 
transcriptionally or post-transcriptionally in the down-regu- 
lation of receptor. We are currently working to identify the 
precise autoregulatory signals within the hGR cDNA and 
understand their mechanism of action. 
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